The MMprofilerTM with SKY92 CE-IVD kit can be run locally in your own lab or as a service from the SkylineDx central laboratory. This flexibility delivers important benefits to both clinicians and hospitals:

  • utilizes proven CE-market microarray technology

  • provides local access to gene-based risk identification testing

  • robust technology reduces turnaround time to days, not weeks

United States
The SKY92 is available as a CLIA validated Laboratory Developed Test (LDT) in the United States. Currently we are running a prospective multicenter study to measure the impact of SKY92 on treatment intention in active multiple myeloma patients in the United States. Click here for more information about this clinical study.



  • Columbia UMC in New York, New York

  • Hackensack UMC in Hackensack, New Jersey, United States

  • Levine Cancer Institute in Charlotte, North Carolina, United States

  • Lombardi Comprehensive Cancer Center in Washington DC, United States

  • Medical College of Wisconsin in Milwaukee, Wisconsin, United States

  • Weill Cornell Medicine, New York, New York, United States